<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <title></title>
        <meta name="description" content="">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        <link rel="stylesheet" href="css/styles.css">
        <link rel="stylesheet" href="css/customStyles.css">
    </head>
    <body class="home">
        <div id="header">
            <div class="header agilvaxLogoSmallScreen center">
                <a href="index.html"><img src="images/agilvaxHeaderLogo.png" alt="Agilvax" title="Agilvax" width="135"></a>
            </div>

            <div class="navigation">
                    <div class="mobileNavToggle">Menu</div>
                    <div class="navigationBar">
                        <ul class="nav navLeft">
                        </ul><!-- /nav -->
                        <ul class="nav navRight">
                        </ul><!-- /nav -->
                    </div><!-- /navigationBar -->
            </div><!-- /navigation -->
        </div><!-- #header -->

        <div class="pageTitle">
            <ul class="slides center">
                <li>
                    <div class="containerNarrow">
                        <h1 class="slideInBT">Vaccines Moving Forward</h1>
                        <p class="slideInBT" style="font-size:20px;">Agilvax is revolutionizing the discovery and development of immunotherapies and targeted vaccines.</p>
                        <p><a href="techPlatform.html" class="btn primaryBtn">Learn  More About The Agilvax VLP Platform</a></p>
                    </div>
                </li>
            </ul>
        </div><!-- /pageTitle -->
        <div class="mainContent hl">
                <div class="container">
                    <div class="oneThird">
                        <a href="docs/Agilvax-Fact-Sheet-NIH.pdf" class="card" title="Agilvax Download Fact Sheet" target="_blank">
                            <div class="agilvaxDownladFactSheetWrapper">
                                <img src="images/agilvaxFactSheetDownloadBtn.png" alt="Agilvax Download Fact Sheet" title="Agilvax Download Fact Sheet">
                            </div><!-- /agilvaxDownladFactSheetWrapper -->
                        </a>
                    </div><!-- /oneThird -->
                    <div class="oneThird">
                        <div class="card">
                            <h3>Agilvax’s Unique VLP Technology Platform</h3>
                            <p>Agilvax develops cancer immunotherapies and targeted vaccines for infectious diseases utilizing its proprietary virus-like-particle (VLP) platform technology.</p>
                            <ul class="listNavigation">
                                <li><a href="techPlatform.html" title="Learn more about the Agilvax VLP Platform">Learn more about the Agilvax VLP Platform</a></li>
                                <li><a href="techAdvantages.html" title="Learn more about the technical advantages">Learn more about the technical advantages</a></li>
                            </ul>
                        </div><!-- /card -->
                    </div><!-- /oneThird -->
                    <div class="oneThird gridLast">
                        <div class="card">
                                <h3><a href="news.html">Agilvax News</a></h3>
                                    <ul class="listNavigation agilvaxNews">
                                        <li>
                                            <a href="nAgilvax-IBT.html">Agilvax Announces Strategic Collaboration with Integrated BioTherapeutics to Develop a Novel Pan-Ebola Vaccine</a>
                                            <span class="date">July 20, 2015</span>
                                        </li>
                                        <li>
                                            <a href="nNMSBA.html">Agilvax To Collaborate With Sandia National Laboratories & NMSBA To Develop Vaccines And Immunotherapies That Lack Cold-chain Requirements</a>
                                            <span class="date">May 12, 2015</span>
                                        </li>
                                        <li>
                                            <a href="n-Agilvax-Present-At-ChinaBio-Partnering-Forum-2015.html">Agilvax To Present At The 2015 Annual Conference On Vaccine Research and Attend The 7th Annual ChinaBio Partnering Forum</a>
                                            <span class="date">April 8, 2015</span>
                                        </li>
                                    </ul>
                            </div><!-- /card -->
                            </div><!-- /oneThird gridLast -->
                </div><!-- /container -->
        </div><!-- /mainContent -->

       
        <div class="mainContent2 grayBg">
            <div class="containerNarrow">
                    <h3>The Agilvax platform has been used to develop immunotherapies to combat cancer.</h3>
                <div class="oneThird">
                    <a href="cancerBreastCancer.html" class="greenCard AgilvaxSolution">
                        <p>Breast Cancer<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneThird -->
                <div class="oneThird">
                    <a href="cancerLungCancer.html" class="greenCard AgilvaxSolution">
                        <p>Lung Cancer<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneThird -->
                <div class="oneThird gridLast">
                    <a href="cancerMelanoma.html" class="greenCard AgilvaxSolution">
                        <p>Melanoma<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneThird gridLast -->
                <div class="clear"></div>

                <hr class="halfLightBlue">    
                <h3>Platform has been used to develop vaccine candidates to combat:</h3>
                <div class="oneHalf">
                    <a href="infDisHPV.html" class="greenCard AgilvaxSolution">
                        <p>Human Papilloma Virus<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneHalf -->
                <div class="oneHalf gridLast">
                    <a href="infDisRSV.html" class="greenCard AgilvaxSolution">
                        <p>Respiratory Syncytial Virus<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneHalf gridLast -->
                <div class="oneHalf">
                    <a href="InfDisMalaria.html" class="greenCard AgilvaxSolution">
                        <p>Malaria<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneFourth -->
                <div class="oneHalf gridLast">
                    <a href="infDisDengue.html" class="greenCard AgilvaxSolution">
                        <p>Dengue<br><span class="caption">Click to Learn More</span></p>
                    </a>
                </div><!-- /oneHalf gridLast -->
            </div><!-- /containerNarrow -->
            <div class="clear"></div>
        </div><!-- /mainContent2 -->

        <div class="mainContent3">
            <div class="containerNarrow center">
                <h3>About Agilvax</h3>
                <p>Agilvax is a privately held company with headquarters in Albuquerque, NM that discovers and develops potent vaccines and immunotherapies targeting infectious diseases and cancer. Agilvax is able to rapidly identify and select lead immunotherapy candidates through the power of the body’s own immune system in combination with Agilvax’s proprietary virus like particle (VLP) platform technology.</p>
                <div class="oneHalf">
                    <p><a href="about.html" class="btn primaryBtn">Learn More About Us</a></p>
                </div><!-- /oneHalf -->
                <div class="oneHalf gridLast">
                    <p><a href="team.html" class="btn primaryBtn">Meet The Team</a></p>
                </div><!-- /oneHalf gridLast -->
            </div><!-- /containerNarrow -->
            <div class="clear"></div>
        </div>

        <div id="footer">
        </div><!-- /footer -->

        <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
        <script src="http://ajax.googleapis.com/ajax/libs/jqueryui/1.10.4/jquery-ui.min.js"></script>
        <script src="js/modernizr-2.6.2.min.js"></script>
        <script src="js/plugins.js"></script>

        <!-- LoadIncludes -->
        <script>
            $( ".navLeft" ).load( "includes/nav.html" );
            $( ".navRight" ).load( "includes/navRight.html" );
            $( "#footer" ).load( "includes/footer.html" );
        </script>
        <script src="js/main.js"></script>

    </body>
</html>
